Prognostic Potential Cell Surface Markers CD47 / CD27 / CD8 and Pim-kinase in Patients With Hematologic Malignancies or Solid Tumors
Conditions
Solid Tumor - Ovarian Cancer - Non-small Cell Lung Cancer - Chronic Lymphocytic Leukemia - Burkitt's Lymphoma
Conditions: official terms
Burkitt Lymphoma - Carcinoma, Non-Small-Cell Lung - Leukemia, Lymphocytic, Chronic, B-Cell - Leukemia, Lymphoid
Conditions: Keywords
Paraproteinemias, Blood Protein Disorders, Hematologic Diseases, Hemorrhagic Disorders, Lymphoproliferative Disorders, Immunoproliferative Disorders, Immune System Diseases
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Retrospective
Overall Status
Recruiting
Summary
The purpose of this study is to understand if small proteins found on the surface of tumor cells (called CXCR4, CD47,CD27,CD8) or inside the tumor cells (Pim kinases, sphingolipids, and pS6) can predict how patients will respond to chemotherapy-treatment and if a small molecule inside the tumor cells (called Pim kinase) can be used as a treatment target patients with selected refractory or relapsed hematologic malignancies or solid tumors. A sample from the bone marrow biopsy (a small amount of tissue removed from the body for laboratory testing), biopsy of the tumor and aspirate (a small amount of fluid is removed from the body for laboratory testing) that had been done before the subject entered this study will be provided for research purposes. Based on preliminary data, it is hypothesized that CD27,CXCR4, CD47, sphingolipids, and Pim kinases could be used as prognostic/predictive markers and that Pim kinase inhibitors provide a new agent for the treatment in patients with selected refractory or relapsed hematologic malignancies or solid tumors
Detailed Description
Primary Outcome Measures:

- Measure the expression levels of CXCR4, CD47,CD27, CD8 and pS6 by flow cytometry with hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors via patient's marrow aspirate

- [ Time Frame: 3 years ]

- [ Designated as safety issue: No ] The investigators Aim 1 is to perform a corrective study to measure the expression levels of CXCR4, CD8, CD47,CD27, pS6 by flow cytometry in patient's marrow aspirate and correlate their expression level with patients' treatment responses

Secondary Outcome Measures:

• Determine if Pim kinase inhibitors or sphingosine kinase 2 inhibitors will inhibit patients' tumor cells [ Time Frame: 3 years ] [ Designated as safety issue: No ] The investigators aim 2 involves only in vitro cell culture system and in vivo animal models. The investigators will measure the efficacy of Pim kinase inhibitors in inhibiting patients' tumor cell growth in vitro using cell culture system. The investigators will also determine the efficacy of Pim kinase inhibitors and sphingosine kinase 2 inhibitors in inhibiting tumor growth of patients in animal models. The investigators will measure the tumor size in animal models. The investigators Aim 2 does not involve any measurement of human with hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors. Therefore, measures of safety, tolerability etc in patients are not applicable.

Bio specimen Retention: Samples With DNA
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- A diagnosis hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors with bone marrow aspirate/biopsy who will have a bone marrow biopsy and aspirate

- Planned therapy with standard chemotherapy for hematologic cancers (certain leukemias and lymphomas), as well as patients with select types of solid tumors Laboratory data such as calcium, beta 2-microglobulin, albumin, creatinine and bone survey available for staging purpose.

- ≥18 years old

Exclusion Criteria:

- < 18 years old

- Patients whose treatment records are not available
Location
ul.Gazety Pravda 96
Dnepropetrovsk, Ukraine
Status: Recruiting
Contact: Andrew Petrov, MD - +380957883828
Start Date
November 2013
Completion Date
February 2017
Sponsors
Cancer Centre of Monoclonal Therapy, LLC
Source
Cancer Centre of Monoclonal Therapy, LLC
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page